Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 12/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23709640 | 1.00 | GNAO1 (0.44) | GNAO1GNAI3GNAI1EPHX1DNM1 | |
| SCHEMBL18922334 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20626600 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20004243 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20093568 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL18557836 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL20306106 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL21703732 | 0.98 | GNAO1 (0.42) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL19772438 | 0.94 | GNAO1 (0.43) | GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL11280750 | 0.94 | GNAO1 (0.40) | GNAO1GNAI3GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | GNAO1 1898/4885GNAI3 485/4885GNAI1 433/4885 |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | GNAO1 4302/4885GNAI3 3239/4885GNAI1 3626/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | GNAO1 4302/4885GNAI3 3239/4885GNAI1 3626/4885 |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | GNAO1 1925/4885GNAI3 2275/4885GNAI1 1343/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | GNAO1 1154/4885GNAI3 1479/4885GNAI1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.